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Abstract
Introduction:  Enteral  Nutrition  Therapy  (ENT)  is  considered  an  important  tool  for  the  appropri-
ate maintenance  of  nutritional  conditions.  ENT  tolerance  may  be  limited  due  to  gastrointestinal
(GI) events  resulting  from  formula  composition  and/or  simultaneously  administered  drug  ther-
apies.
Aims: To  verify  the  possible  association  between  GI  events  and  drug  therapies  being  adminis-
tered to  patients  receiving  ENT  at  a  university  hospital.
Methods:  A  prospective  observational  cohort  study  was  conducted.  Medical  records  from  95
patients requiring  ENT  at  the  Hospital  de  Clínicas  de  Porto  Alegre  (HCPA)  were  randomly  eval-
uated until  discharge,  death,  or  initiation  of  oral  or  parenteral  diet  occurred.  Details  of  the
administered  medications  and  enteral  formula,  together  with  the  presenting  patient  disease  and
digestive  manifestations,  were  recorded  by  the  medical  team.  Three  experienced  gastroenterol-
ogists evaluated  the  possible  association  between  the  digestive  symptoms  and  the  medications
employed. The  study  protocol  was  approved  by  the  HCPA  Research  Ethics  Committee  and  patient
consent forms  were  signed.
Results:  Mean  patient  age:  65  ±  17  (24-95)  years;  94.70%  presented  with  GI  events:  constipation
70.50%, diarrhea  38.90%,  abdominal  distension  18.90%,  vomiting  16.80%,  and  pulmonary  aspi-
ration 1.10%.  ENT  was  most  indicated  in  neurologic  (50.50%)  and  neoplastic  (25.30%)  disease.
Medications  given  to  the  patients  showed  a  positive  relation:  63.20%  to  86.70%  of  GI  symptoms
could be  attributed  to  the  drugs  being  administered.
Conclusions:  GI  complications  during  ENT  are  common;  they  are  frequently  linked  to  admin-
istered drug  therapy.  Health  care  teams  should  consider  all  risk  factors  present,  speciﬁcally
those related  to  prescribed  medication,  before  modifying/suspending  ENT.
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Asociación  entre  el  uso  de  medicamentos  y  efectos  adversos  gastrointestinales  en
pacientes  que  reciben  terapia  con  nutrición  enteral  en  un  Hospital  Universitario
Resumen
Introducción:  La  terapia  de  apoyo  con  nutrición  enteral  (TNE)  se  considera  una  herramienta
importante  para  el  mantenimiento  adecuado  de  la  condición  nutricional.  La  tolerancia  de  la
TNE puede  estar  limitada  por  los  efectos  gastrointestinales  (GI)  que  resultan  de  la  composición
de la  fórmula  y/o  de  tratamientos  farmacológicos  administrados  simultáneamente.
Objetivo: Determinar  la  posible  asociación  entre  efectos  GI  y  tratamientos  farmacológicos
administrados  simultáneamente,  a  pacientes  que  reciben  TNE  en  un  Hospital  Universitario.
Métodos: Se llevó  a  cabo  un  estudio  prospectivo  observacional  de  cohorte.  Los  expedientes
médicos  de  95  pacientes  que  requirieron  TNE  en  el  Hospital  de  Clínicas  de  Porto  Alegre  (HCPA)
fueron aleatoriamente  evaluados  hasta  que  ocurriera  su  egreso,  muerte  o  iniciación  de  vía  oral
o dieta  parenteral.  El  equipo  médico  registró  los  detalles  de  los  medicamentos  administrados
y la  fórmula  enteral  en  conjunto  con  la  enfermedad  presentada  por  los  pacientes,  así  como  las
manifestaciones  digestivas.  Tres  gastroenterólogos  experimentados  evaluaron  la  posible  aso-
ciación entre  los  síntomas  digestivos  y  los  medicamentos  utilizados.  El  protocolo  de  estudio
fue aprobado  por  el  Comité  de  Investigación  y  Ética  del  HCPA;  y  los  pacientes  ﬁrmaron  un
consentimiento  informado.
Resultados:  La  edad  media  de  los  pacientes  fue:  65  ±  17  (24-95)  an˜os;  9470%  presentó  efec-
tos GI:  estren˜imiento  7050%,  diarrea  38,90%,  distensión  abdominal  18,90%,  vómito  16,80%,  y
aspiración pulmonar  1,10%.  La  TNE  fue  indicada  con  mayor  frecuencia  en  enfermedades  neu-
rológicas  (50,50%)  y  neoplásicas  (25,30%).  Los  medicamentos  administrados  a  los  pacientes
mostraron una  relación  positiva:  63,20%  a  86,70%  de  los  efectos  GI  fueron  atribuidos  a  los
tratamientos  farmacológicos.
Conclusiones:  Las  complicaciones  GI  durante  TNE  son  comunes.  Se  asocian  con  frecuencia  a
los tratamientos  farmacológicos  administrados.  Los  equipos  encargados  del  cuidado  de  la  salud
de estos  pacientes  deben  considerar  todos  los  factores  de  riesgo  presentes,  especíﬁcamente
aquellos relacionados  con  los  medicamentos  ordenados  antes  de  modiﬁcar/suspender  la  TNE.
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astrointestinal  (GI)  events  in  Enteral  Nutrition  Therapy
ENT)  may  be  a  result  of  the  nutritional  formula  that  is
nfused,  the  drug  therapy  being  taken  by  these  patients,
r  the  background  illness  justifying  its  use.1 Adverse  events
ccurring  from  medications  can  vary  depending  on  the  drug
rescribed,  as  well  as  on  the  clinical  condition  of  the
atient.  Medications  to  be  administered  should  be  carefully
valuated  in  order  to  prevent  such  problems,  primarily  in
he  hospital  setting  where  patients  are  undergoing  multiple
rug  therapies.2 Few  studies  have  attempted  to  investigate
his  association  between  medication  use  and  patients  in  such
 scenario.
The aims  of  this  study  were  to  verify  the  frequency
f  GI  complications  (diarrhea,  abdominal  distension,  nau-
ea/vomiting,  and  constipation)  associated  with  the  use  of
NT  in  adult  inpatients  at  the  Hospital  de  Clínicas  de  Porto
legre  (HCPA),  and  to  identify  the  possible  association  with
edications  simultaneously  administered  during  treatment.
ethodsesign  and  patients
 prospective  observational  cohort  study  was  conducted
sing  data  collected  from  medical  records  of  the  HCPA
d
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r
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npatients  requiring  enteral  nutrition  support.  The  sample
ncluded  patients  with  a  minimum  age  of  18  years  that
equired  ENT  for  more  than  ﬁve  days.  Patients  receiving  par-
nteral  nutrition,  enteral  nutrition  for  less  than  ﬁve  days,
ral  intake  concomitant  with  enteral  nutrition,  pregnant
omen,  and  women  who  had  recently  given  birth  were
xcluded  from  the  study.
The  study  was  approved  by  the  Research  Ethics  Com-
ittee  of  the  HCPA  and  consent  forms  were  signed  by  all
articipants.
ata  collection
he  prospective  selection  of  study  participants  was  carried
ut  from  a  list  of  ENT  users  at  the  HCPA, using  the  existing
nstitutional  database  that  is  part  of  its  electronic  medical
rescription  system.  Patients  were  enumerated  consecu-
ively  by  placing  numbered  cards  in  a  container  and  drawing
hem  out  at  random.  Data  from  electronic  medical  records
ere  collected  from  day  ﬁve  of  ENT  up  to  therapy  interrup-
ion  due  to  patient  discharge  or  death  or  to  the  beginning
f  an  oral  or  parenteral  diet.  Medical  records  were  analyzed
hree  times  a  week  by  the  same  researcher  on  alternating
ays.  The  evaluations  of  the  medical  team  and  nursing  staff
ere  noted,  along  with  medication  prescriptions  and  occur-
ences  of  GI  complications  during  the  previous  48  h  to  72  h.
hese  data  were  entered  in  the  electronic  chart  system  of
rologic  events  163
Table  1  Sample  characteristics.
Variables  Average
Age  (mean  ±  SD) 65  ±  17  years
Patients  with  adverse  effects  (%) 94.70
Continuous  technique  (%) 77.90
Diet  osmolality  (mean  ±  SD)  385  ±  47  mOsm/L
Fiber infusion  (per  day)  20.7  g
Prescription  of  semirecumbent  body
position  (%)
96.80
Diet  duration
(median  [25th-75th percentile])  26  (15-45)  days
Clinical  diagnosis (%)
Neurologic  diseases 50.50
Neoplastic  diseases  25.30
Human  Immunodeﬁciency  Virus  4.20
Chronic  renal  failure  4.20
Dysphagia  1.10
Othersa 14.70
SD: standard deviation.
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the  HCPA, where  all  patient  information  is  consolidated.  The
most  recent  electronic  record  was  used  for  those  patients
that  were  discharged  or  that  died  on  days  when  data  were
not  collected.
The  nursing  team  responsible  for  the  daily  hospital  rou-
tine  was  not  aware  of  the  study  objective,  in  order  to  avoid
the  Hawthorne  effect.3
A  data  collection  instrument  was  developed  to  evaluate
the  clinical  GI  manifestations  of  patients,  the  medications
administered,  and  the  possible  association  between  these
two  variables.  The  patients’  observed  GI  symptoms  were
described  using  the  following  terminology:
a)  Deﬁned  relationship:  events  with  a  high  probability  of
being  caused  by  medications  used  during  the  period
of  drug  therapy;  a  cause-effect  relationship  stated
as  complications  described  on  the  patient  information
leaﬂet  that  could  not  be  explained  by  known  character-
istics  of  the  illness.
b)  Probable  relationship:  events  with  a  low  probability  of
being  caused  by  medications  used  during  the  period
of  drug  therapy;  complications  described  on  the  patient
information  leaﬂet  that  could  not  be  explained  by  known
characteristics  of  the  illness.
c)  Possible  relationship:  events  with  a  very  low  probability
of  being  caused  by  medications  used  during  the  period  of
drug  therapy  and  that  could  more  likely  be  explained  by
known  characteristics  of  the  patient’s  clinical  condition.
d)  Doubtful  relationship:  events  with  a  greater  probabil-
ity  of  being  linked  to  factors  other  than  the  medication
under  scrutiny.
Three  gastroenterologists  familiar  with  the  terminol-
ogy  used  in  the  data  collection  instrument  independently
evaluated  the  medications  taken  by  the  patients  and  any
subsequent  GI  events  that  were  registered.  In  cases  in
which  there  was  a  difference  of  opinion,  the  evaluators
met  together  to  work  out  a  consensus.  For  data  analy-
sis  purposes,  the  terms  ‘‘probable’’  and  ‘‘possible’’  were
considered  to  be  a  positive  association,  whereas  the  term
‘‘doubtful’’  implied  a  negative  association.
Outcomes  measurement
Diarrhea  was  deﬁned  as  the  occurrence  of  three  or  more
episodes  of  liquid  or  semi-liquid  evacuations  within  a  24-
hour  timespan.4 Constipation  was  deﬁned  as  less  than  three
evacuations  occurring  per  week.4,5 Pulmonary  aspiration  was
conﬁrmed  by  clinical  criteria/symptoms  reported  and/or
by  radiologic  method  (data  present  in  medical  records).
Abdominal  distension,  nausea,  and  vomiting  were  included
when  reported  by  the  medical  team  in  daily  patient  eval-
uations.  Medical  records  were  used  to  obtain  information
regarding  the  medical  prescription  for  body  positioning  of
the  patient  in  bed.
Sample  calculationsA  total  of  95  patients  using  ENT  were  evaluated,  result-
ing  in  an  approximate  42.00%  frequency  value  of  adverse
gastroenterologic  and  pulmonary  events,  with  a  maximum
s
t
sa Diabetes mellitus, heart failure, anemia, malnutrition, sep-
sis, bipolar disorder, laryngoﬁssure, postoperative recovery.
cceptable  difference  of  10.00%.  These  adverse  events
ncluded  diarrhea,  abdominal  distension,  nausea/vomiting,
onstipation,  and  clinical  evidence  of  pulmonary  aspiration.
he  margin  of  error  calculation,  which  varied  from  8.00%  to
0.00%,  was  used  for  the  grouped  outcomes  when  they  were
valuated  separately.
ata  analysis
alculations  of  frequency,  percentage,  mean  ±  standard
eviation  (SD),  and  median  (including  the  25th and  75th per-
entiles)  were  performed  for  the  descriptive  data  analysis.
earson’s  chi-squared  test  and  Fisher’s  exact  test  were  used
o  compare  categorical  variables  between  groups  that  did
r  did  not  present  adverse  gastroenterological  events.  The
elationship  between  GI  complications  and  osmolality  was
alculated  using  a  Student’s  t test.  The  Mann-Whitney  test
as  used  to  evaluate  the  relationship  of  adverse  events
ith  the  duration  of  enteral  nutrition.  Concordance  among
astroenterologists  (in  relation  to  medications  and  adverse
vents)  was  evaluated  using  weighted  Kappa  values.6
esults
he  study  involved  95  patients  with  no  loss  of  follow-up.
Demographic  data  and  population  characteristics  are  pre-
ented  in  Table  1.
The  medical  prescription  for  the  body  positioning  of  the
atient  in  bed  was  not  related  to  the  occurrence  of  clinically
elevant  pulmonary  aspiration,  with  only  one  patient  pre-
enting  this  condition.  Patients  with  diarrhea  used  enteral
iet  for  a  longer  period  of  time  than  those  who  did  not
resent  with  this  complication  (median:  32  days)  (p  =  0.001).Observed  GI  events  that  occurred  in  this  population  are
hown  in  Table  2.  All  prescribed  medications  presented  in
he  medical  records  were  considered  for  the  purpose  of  this
tudy.
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Table  2  Frequency  of  Adverse  Events  (n  =  95  patients).
Adverse  Event  Frequency  (patients)  Percentage  (%)  CI  (95%)
Constipation  67  70.50  60.3--79.4
Diarrhea 37  38.90  29.1--49.5
Abdominal distension  18  18.90  11.6--28.3
Nausea 17  17.90  10.8--27.1
Vomiting 16  16.80  9.9--28.9
Pulmonary aspiration 1 1.10  0.03--5.7
CI: conﬁdence interval.
Note: The sum of cases was greater than 100% because some patients 
The  weighted  Kappa  values,  which  analyzed  the  concur-
rence  between  gastroenterologists  in  relation  to  the
evaluated  variables,  showed  a  variation  of  0.45-0.62,  an
interval  considered  moderate  to  good.6,7 The  frequency  of
adverse  events  in  relation  to  the  negativity  and  positivity
of  association  with  medications  used  by  patients  during  their
stay  at  the  HCPA  is  shown  in  Table  3.
Table  4  shows  the  medications  frequently  associated  with
adverse  gastroenterological  events  in  this  sample.
Discussion
We  believe  that  this  is  the  ﬁrst  study  attempting  to  evalu-
ate  the  relationship  between  GI  events  and  simultaneously
administered  pharmacologic  agents  in  hospitalized  patients
being  treated  with  ENT.
Our  results  conﬁrm  a  high  incidence  of  digestive  symp-
toms  in  this  population,  with  constipation  and  diarrhea  being
the  most  important  manifestations.
Table  3  Frequency  of  Adverse  Events  related  to  their  asso-
ciation  with  medications.
Event  Positive
relation
Negative
relation
Vomiting 87.60%  12.40%
Diarrhea  80.50%  19.50%
Nausea 80.00%  20.00%
Constipation 63.70%  36.30%
Abdominal  distension 63.20%  36.80%
Table  4  Medications  frequently  associated  with  Adverse
Gastroenterologic  Events.
Adverse  Event  Medications
Diarrhea  Laxatives,  antibiotics,  oncologic
agents,  medications  with  sorbitol,
antiretrovirals
Constipation  Antiparkinsonians  such  as
levodopa  and  carbidopa,  opioids,
nonsteroidal  anti-inﬂammatory
drugs,  ferrous  sulfate,  diuretics
Nausea/Vomiting  Oncologic  agents,  opioids,
antibiotics
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The  occurrence  of  diarrhea  was  higher  in  the  group  of
atients  that  received  ENT  for  a  longer  period  of  time.
his  fact  can  be  explained  by  the  multifactorial  causes  of
iarrhea.  The  aggravation  of  diarrhea  can  occur  in  patients
ith  longer  periods  of  hospitalization,  extensive  use  of
edications  (laxatives,  medications  that  contain  sorbitol,
ntibiotics,  and  oncologic  agents),  or  as  a  result  of  underly-
ng  illnesses  or  medical  conditions  (such  as  diabetes  mellitus
r  contamination  with  the  Human  Immunodeﬁciency  Virus-
IV).1,8 It  is  worth  noting  that  in  our  sample,  patients  who
ere  using  antibiotic  therapy  presented  higher  frequencies
f  diarrhea,  which  agrees  with  ﬁndings  from  other  studies.8,9
When  comparing  our  results  to  a  study  conducted  by  Luft
t  al.10 involving  302  patients  receiving  or  not  receiving
NT  and  that  represented  a population  with  similar  char-
cteristics  to  ours  in  terms  of  patient  age,  number  of  days
f  hospitalization,  applied  deﬁnition  of  diarrhea,  and  type  of
iet  used,  the  prevalence  of  diarrhea  was  found  to  be  18.20%
s  opposed  to  the  38.90%  obtained  in  our  study.  Methodologi-
al  data  collection  differences  were  probably  responsible  for
his  discrepancy.
The  medications  most  frequently  associated  with  diar-
hea  involved  stimulants  or  osmotic  laxatives  for  the
reatment  of  constipation,  such  as  mineral  oil,  lactulose,
isacodyl,  and  also  the  use  of  antibiotics.11,12
Approximately  two-thirds  of  our  sample  (70.50%)  pre-
ented  with  constipation.  This  result  represented  a  higher
ercentage  than  that  found  in  studies  conducted  by
ontejo13 (15.70%)  and  Pancorbo-Hidalgo  et  al.14 (29.80%).
owever,  it  was  comparable  to  the  ﬁndings  of  Nassar5
69.90%),  whose  study  design  was  similar  to  ours.  This  result
an  be  explained  by  our  sample  characteristic  in  which
0.50%  of  patients  suffered  from  neurological  diseases
hich  can  predispose  to  constipation  in  a  hospital  setting.
hese  patients  often  spend  longer  periods  of  time  in  bed,  as
ell  as  being  subject  to  certain  constipating  medications
levodopa  and  carbidopa,  for  example)  that  inhibit  both
olonic  motility  and  perception  of  evacuative  impulses.15,16
 lack  of  ﬁber  in  the  ENT  formula  does  not  appear  to  be
elated  to  this  symptom,  as  the  average  daily  ﬁber  infu-
ion  was  20.7  g,  an  amount  within  the  recommended  daily
onsumption.17,18
Few  clinical  studies  have  evaluated  the  risk  associated
ith  medication  use  and  the  occurrence  of  constipation  in
atients  receiving  ENT;  this  association  presented  a  posi-
ive  relationship  in  63.70%  of  our  patients.1 The  occurrence
f  this  clinical  problem  can  be  caused  by  many  med-
cations  regularly  used  in  the  hospital  setting,  such  as
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opioid  analgesics  (morphine,  codeine)  and  nonsteroidal  anti-
inﬂammatory  drugs  (naproxen,  ibuprofen).12,16,19,20
The  underlying  disease  itself  that  necessitates  the  use
of  ENT  is  also  an  important  factor  in  the  occurrence  of  GI
complications.21,22 This  should  be  taken  into  consideration
when  modiﬁcations  to  infused  medications  and/or  changes
in  the  enteral  feeding  formula  are  contemplated,  with  the
aim  of  improving  newly  arising  symptoms  in  the  clinical  set-
ting.
Caution  should  be  exercised  when  making  any  general-
ization  of  the  results  of  this  study,  given  that  our  sample
was  obtained  from  a  university  hospital  context  and  we
had  a  team  of  experienced  health  professionals  with  well-
established  routines  for  the  care  of  patients  requiring  ENT;
the  HCPA  is  a  regional  reference  center  for  health  services
in  Southern  Brazil.
A  limitation  of  this  study  with  respect  to  the  quality
of  information  could  involve  the  method  of  data  collec-
tion  (patient  medical  records),  as  both  under-reporting  and
over-reporting  of  signs  and  symptoms  may  occur.  A  fur-
ther  drawback  to  consider  is  the  lack  of  a  validated  tool
for  evaluating  the  relationship  between  medication  use  and
GI  complications  developed  by  patients.  It  was  necessary
to  create  such  an  instrument  based  on  the  content  of  the
National  Agency  for  Sanitary  Vigilance  (ANVISA),23 as  well
as  the  tool  of  Naranjo  and  Busto24 that  is  widely  used  in
clinical  trials.  This  latter  instrument  could  not  be  used  in
clinical  practice  due  to  methodological  issues,  because  it
attempts  to  study  one  variable  (pharmacologic  interven-
tion)  at  a  time  and  uses  information  related  to  placebo
intervention  in  order  to  deﬁne  the  level  of  association.  For
the  purposes  of  our  study,  we  used  only  the  terminology
and  operational  deﬁnitions  of  Naranjo  and  Busto,  without
using  the  other  characteristics  they  applied  in  their  clinical
research.8,10,13,14
Although  the  instrument  used  had  not  previously  been
validated,  the  Kappa  test  applied  to  evaluate  the  agreement
relationship  between  the  gastroenterologists  considered  it
to  be  moderate  to  good,6,7 which  suggests  that  it  may  be
used  in  a  larger  sample  in  order  to  evaluate  sensitivity,  speci-
ﬁcity,  and  predictive  values.
The  strength  of  this  research  lies  in  the  fact  that  it  is
an  observational  study  set  in  the  real-life  context  of  the
operational  realities  of  enteral  nutrition  application  within
a  tertiary  reference  hospital  in  Southern  Brazil.  Care  was
taken  to  avoid  the  Hawthorne  effect  whereby  behavior  or
performance  can  be  modiﬁed  simply  because  a  person  is
aware  that  they  are  being  evaluated.4 To  this  end,  medi-
cal,  nursing,  and  nutrition  teams  were  never  aware  that  a
researcher  was  collecting  study  data  from  patient  medical
records.  It  was  equally  important  for  the  data  to  be  collected
in  a  randomized  manner,  thus  enabling  a  representative  sam-
ple  of  the  hospital  as  a  whole  to  be  obtained.  Additionally,
all  data  collection  was  conducted  by  the  same  researcher
and  no  sample  loss  occurred,  resulting  in  the  matching  of
the  sample  calculation  with  the  number  of  patients  studied.Conclusions
GI  symptoms  are  frequent  in  patients  using  ENT.  How-
ever,  the  causes  associated  with  them  should  be  carefully
1gic  events  165
xamined  in  the  clinical  context  of  each  patient,  as  they
re  often  connected  to  the  prescribed  medications  that  are
ointly  administered  with  ENT.  Consequently,  enteral  nutri-
ion  per  se  should  not  be  seen  as  a  principal  cause  of  GI
omplications.  Healthcare  teams  should  consider  all  risk
actors  present  for  each  patient  when  evaluating  the  occur-
ence  of  these  adverse  effects,  paying  particular  attention
o  the  prescribed  medications  in  use  before  modifying,
educing,  or  suspending  ENT  administration.
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